Healios KK (FRA:6VX) Net Interest Margin (Bank Only) %

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:6VX Healios KK FRA:6VX
59 GF Score
Price €1.33
GF Value €0.30
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Healios KK Net Interest Margin (Bank Only) %?

Net Interest Margin (Bank Only) % only applies to banks.

FRA:6VX
59GF Score
Healios KK FRA:6VX
Net Interest Margin (Bank Only) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Healios KK (FRA:6VX) Overvalued in 2026?

Based on GuruFocus' analysis, Healios KK stock appears to be overvalued. The current stock price of €1.33 is trading 343.3% above its estimated GF Value™ of €0.30. GuruFocus considers Healios KK to be Significantly Overvalued.

Key valuation signals for FRA:6VX:

  • Net Interest Margin (Bank Only) %:
  • GF Value™: €0.30 vs. price of €1.33 (343.3% above fair value)
  • GF Score™: 59/100 with 5 warning signs

No single metric tells the full story. See the FRA:6VX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Healios KK Business Description

Other Exchanges HLOSF:USA4593:Japan
Address 1-1-2 Yurakucho, Hibiya Mitsui Tower 12Floor, Work Styling, Chiyoda-ku, Tokyo, JPN, 100-0006
Healios KK is involved in development and sales of opthalmological surgery adjuvants and research, development and manufacture of cell therapy products and regenerative medicine products. The company is developing treatments for age-related macular degeneration and organ anlage transplantation therapy. The company develops next-generation cell therapies using a proprietary gene-edited induced pluripotent stem cell (iPSC) platform, with programs targeting immuno-oncology, ophthalmology, liver diseases, ischemic stroke, and acute respiratory distress syndrome.
59GF Score

Get the complete analysis for FRA:6VX

Net Interest Margin (Bank Only) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.33
Price
€0.30
GF Value